JP2022512905A5 - - Google Patents
Info
- Publication number
- JP2022512905A5 JP2022512905A5 JP2021523957A JP2021523957A JP2022512905A5 JP 2022512905 A5 JP2022512905 A5 JP 2022512905A5 JP 2021523957 A JP2021523957 A JP 2021523957A JP 2021523957 A JP2021523957 A JP 2021523957A JP 2022512905 A5 JP2022512905 A5 JP 2022512905A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024188854A JP2025022888A (ja) | 2018-11-01 | 2024-10-28 | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18203993.3 | 2018-11-01 | ||
| EP18203993 | 2018-11-01 | ||
| PCT/EP2019/080004 WO2020089474A1 (en) | 2018-11-01 | 2019-11-01 | Novel antagonistic anti tnfr2 antibody molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024188854A Division JP2025022888A (ja) | 2018-11-01 | 2024-10-28 | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022512905A JP2022512905A (ja) | 2022-02-07 |
| JPWO2020089474A5 JPWO2020089474A5 (https=) | 2022-10-26 |
| JP2022512905A5 true JP2022512905A5 (https=) | 2022-10-26 |
| JP7646542B2 JP7646542B2 (ja) | 2025-03-17 |
Family
ID=64109794
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523957A Active JP7646542B2 (ja) | 2018-11-01 | 2019-11-01 | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 |
| JP2024188854A Withdrawn JP2025022888A (ja) | 2018-11-01 | 2024-10-28 | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024188854A Withdrawn JP2025022888A (ja) | 2018-11-01 | 2024-10-28 | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12441805B2 (https=) |
| EP (1) | EP3873936A1 (https=) |
| JP (2) | JP7646542B2 (https=) |
| KR (1) | KR20210087029A (https=) |
| CN (3) | CN118702818A (https=) |
| AU (1) | AU2019372184A1 (https=) |
| BR (1) | BR112021007995A2 (https=) |
| CA (1) | CA3117864A1 (https=) |
| IL (1) | IL282715A (https=) |
| MX (1) | MX2021005150A (https=) |
| WO (1) | WO2020089474A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023529010A (ja) | 2020-06-12 | 2023-07-06 | ナンチン リーズ バイオラブス カンパニー，リミティド | Ｔｎｆｒ２に結合する抗体およびその用途 |
| US20240043551A1 (en) * | 2020-12-11 | 2024-02-08 | Adlai Nortye Biopharma Co., Ltd. | Anti-tnfr2 antibody and application thereof |
| JP2024502035A (ja) * | 2020-12-31 | 2024-01-17 | ノヴァロック バイオセラピューティクス， リミテッド | Ｔｎｆｒ２に対する抗体およびそれの使用 |
| AU2022212842A1 (en) * | 2021-01-29 | 2023-08-31 | Shandong Simcere Biopharmaceutical Co., Ltd. | Humanized antibody against tnfr2 and use thereof |
| EP4067381A1 (en) | 2021-04-01 | 2022-10-05 | Julius-Maximilians-Universität Würzburg | Novel tnfr2 binding molecules |
| CN116333123A (zh) * | 2021-12-22 | 2023-06-27 | 宝船生物医药科技(上海)有限公司 | 抗tnfr2抗体及其用途 |
| CN119591711B (zh) * | 2024-11-12 | 2026-01-13 | 澳门大学 | 一种抑制性tnfr2单域抗体及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB－特异性抗体及其使用方法 |
| CN1997667A (zh) * | 2004-05-10 | 2007-07-11 | 宏观基因有限公司 | 人源化FcγRⅡB特异性抗体及其使用方法 |
| KR20070084069A (ko) | 2004-10-08 | 2007-08-24 | 도만티스 리미티드 | Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법 |
| CN109517059B (zh) | 2011-06-30 | 2023-03-28 | 中外制药株式会社 | 异源二聚化多肽 |
| PL2953634T3 (pl) | 2013-02-07 | 2021-11-22 | The General Hospital Corporation | Sposoby namnażania lub zubożania limfocytów t-regulatorowych |
| DK3169341T3 (da) | 2014-07-16 | 2019-08-05 | Transgene Sa | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| WO2016156291A1 (en) * | 2015-03-31 | 2016-10-06 | F. Hoffmann-La Roche Ag | Antigen binding molecules comprising a trimeric tnf family ligand |
| EP3294773A1 (en) * | 2015-05-15 | 2018-03-21 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| WO2017040312A1 (en) | 2015-08-28 | 2017-03-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
| CN114605548A (zh) * | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| WO2017083525A1 (en) | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
| CA3023930C (en) * | 2016-05-13 | 2025-09-23 | The General Hospital Corporation | TUMOR-ANTAGONISTIC ANTIBODIES OF THE NECROSIS FACTOR RECEPTOR SUPERFAMILY |
| ES2941972T3 (es) * | 2016-06-22 | 2023-05-29 | Univ Paris Val De Marne | Prevención o tratamiento de la recaída de neoplasias malignas hematológicas mediante un antagonista de TNFR2 |
-
2019
- 2019-11-01 CN CN202411004492.1A patent/CN118702818A/zh active Pending
- 2019-11-01 WO PCT/EP2019/080004 patent/WO2020089474A1/en not_active Ceased
- 2019-11-01 KR KR1020217012926A patent/KR20210087029A/ko active Pending
- 2019-11-01 AU AU2019372184A patent/AU2019372184A1/en active Pending
- 2019-11-01 BR BR112021007995-5A patent/BR112021007995A2/pt unknown
- 2019-11-01 MX MX2021005150A patent/MX2021005150A/es unknown
- 2019-11-01 CA CA3117864A patent/CA3117864A1/en active Pending
- 2019-11-01 CN CN201980071097.6A patent/CN112955469B/zh active Active
- 2019-11-01 CN CN202411004493.6A patent/CN118667024A/zh active Pending
- 2019-11-01 EP EP19805901.6A patent/EP3873936A1/en active Pending
- 2019-11-01 US US17/290,352 patent/US12441805B2/en active Active
- 2019-11-01 JP JP2021523957A patent/JP7646542B2/ja active Active
-
2021
- 2021-04-27 IL IL282715A patent/IL282715A/en unknown
-
2024
- 2024-10-28 JP JP2024188854A patent/JP2025022888A/ja not_active Withdrawn
-
2025
- 2025-09-04 US US19/318,835 patent/US20250388690A1/en active Pending